Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States; German Center for Neurodegenerative Diseases, Magdeburg, Germany.
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, United States.
Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.
The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ) patients with mild cognitive impairment (MCI) or AD-dementia underwent [F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake in Braak composite regions, (iii) several whole-brain measures of tracer uptake, (iv) regional uptake in AD-vulnerable voxels, and (v) uptake in a priori defined regions. Receiver operating curves characterized accuracy in distinguishing Aβ controls from AD/MCI patients and yielded tau positivity cutoffs. Clinical relevance of tau PET measures was assessed by regressions against cognition and MR imaging measures. Key tracer uptake patterns were identified by a factor analysis and voxel-wise contrasts. Braak staging, global and region-specific tau measures yielded similar diagnostic accuracies, which differed between cohorts. While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe. Key regions of tau accumulation included medial temporal and inferior/middle temporal regions, retrosplenial cortex, and banks of the superior temporal sulcus. Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology. However, regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline.
tau 特异性正电子发射断层扫描(PET)示踪剂的最新发展使得能够对 tau 病理学的区域进行体内定量,这是阿尔茨海默病(AD)的关键病变之一。tau PET 成像可能成为临床诊断和疾病进展跟踪的有用生物标志物,但目前尚未就如何最好地定量 tau PET 信号达成共识。本研究的目的是评估多种全脑和区域特异性方法来检测具有临床意义的 tau PET 信号。两组认知正常的成年人和淀粉样蛋白阳性(Aβ)的轻度认知障碍(MCI)或 AD 痴呆患者接受了 [F]AV-1451 PET 检查。tau 示踪剂定量方法包括:(i)体内 Braak 分期,(ii)Braak 综合区域的摄取,(iii)几种全脑示踪剂摄取测量,(iv)AD 易损区的摄取,和(v)预先定义区域的摄取。接收器操作曲线用于区分 Aβ 对照与 AD/MCI 患者的准确性,并得出 tau 阳性的截止值。通过回归分析认知和磁共振成像测量值来评估 tau PET 测量值的临床相关性。通过因子分析和体素对比确定了关键示踪剂摄取模式。Braak 分期、全局和区域特异性 tau 测量值具有相似的诊断准确性,这在两个队列之间有所不同。虽然所有 tau 测量值都与淀粉样蛋白和整体认知相关,但记忆和海马/内嗅皮层体积/厚度与内侧颞叶的区域示踪剂保留相关。tau 积累的关键区域包括内侧颞叶和下/中颞叶、后扣带回皮质和上颞回沟。我们的数据表明,全脑 tau PET 测量值可能是检测 AD 相关 tau 病理学的充分生物标志物。然而,涵盖 AD 易损区域的区域测量值可能会提高对早期 tau PET 信号、萎缩和记忆下降的敏感性。